Medullary breast carcinoma (MBC) is a rare pathological type of breast cancer. The rate of p53 protein accumulation is higher in MBC than in common invasive ductal carcinoma. Whether this particular feature of MBC influences the outcome after treatment is unknown. We retrospectively analyzed the characteristics, treatment and outcome of 71 patients with MBC treated between 1981 and 1996. The median age was 51 years (range 27-81) and the median clinical tumor size was 25 mm (range 0-70 mm). Breast-conserving treatment was offered when possible: 55 patients had undergone a tumorectomy and radiotherapy while 16 patients had undergone a mastectomy. p53 protein accumulation was determined by immunohistochemistry on paraffin-embedded tumor specimens from 58/71 samples available for this study. The median follow-up for the 56 survivors was 113 months (range 30-241). The 10-year survival and metastasis-free survival rates were 81% and 81.4%, respectively. The local recurrence rate was 16.4%. The two factors predicting outcome were pathological axillary node involvement in the 60 patients who underwent axillary dissection and adjuvant chemotherapy. p53 accumulation was found in 33/58 patients (57%). p53 status was not predictive of survival nor of distant or local recurrences. We confirm that medullary breast carcinoma has a favorable prognosis despite its aggressive pathological features. p53 protein accumulation, found in the majority of MBCs, was not related to outcome. (Int J Biol Markers, 2003; 18: 99-105)
INTRODUCTION
The frequency of medullary breast carcinomas (MBC) varies from 2% to 8.2% of breast carcinomas (1) . This particular form of breast cancer was first described by Moore and Foote in 1949 (2) . It is a circumscribed tumor with a predominantly syncytial growth pattern, nuclear pleomorphism, high mitotic index, and a moderate to pronounced stromal lymphoplasmacytic infiltrate. In comparison with common invasive ductal breast carcinomas, this aggressive histological pattern contrasts with a relatively favorable prognosis (1) (2) (3) (4) (5) (6) . In a previous study we demonstrated that MBC is a highly radiosensitive tumor (7) .
The most common changes of the TP53 gene in human cancers are point missense mutations within the coding sequences. Such mutations are found in all major tumor types, including cancers of the colon, stomach, breast, lung, brain and esophagus. It is estimated that TP53 mutation is the most frequent genetic event in human cancers, accounting for more than 50% of cases. More than 90% of the point mutations reported so far are clustered between exons 4 and 10. One of the most striking features of the inactive mutant p53 protein is its increased stability, with a half-life of several hours compared to 20 minutes for wild-type p53, and its accumulation in the nucleus of neoplastic cells. Therefore, positive immunostaining is an indication of abnormalities of the TP53 gene and its product. Several authors (8) (9) (10) (11) (12) (13) (14) (15) (16) have analyzed TP53 status by both immunohistochemistry (IHC) and DNA sequencing (DNA-S) in breast cancer. The rate of TP53 mutations was rather low (20%), whereas p53 accumulation was found in 30-40% of tumors. Furthermore, there is a high variability in the intensity of staining. Some authors (10, (17) (18) (19) studied the p53 staining rate in very small series of medullary breast carcinomas and observed staining in 40% to 68% of tumors. We recently analyzed a series of 23 MBC with IHC and DNA-S to detect TP53 alterations (20) . We observed excellent agreement between the two techniques. In all cases of TP53 mutations leading to amino-acid modifications (14 cases) we observed p53 overexpression by IHC. Furthermore, when TP53 mutation did not lead to aminoacid changes or in case of a codon stop leading to a truncated protein which was not recognized by p53 antibody (3 cases), we did not observe p53 overexpression by IHC. Typical medullary breast carcinomas (15 cases) were characterized by a 100% TP53 mutation rate with DNA-S and an 86.6% (13/15) p53 overexpression rate with IHC; the remaining two tumors expressed short truncated and unstable p53 protein (no p53 accumulation).
The aims of this study were 1) to retrospectively analyze outcome in a large series of MBC, and 2) to assess p53 overexpression in order to retrospectively evaluate its prognostic value.
MATERIAL AND METHODS

Patient selection
Between January 1981 and July 1996, 128 patients with unilateral non-metastatic medullary breast carcinomas were identified in the Institut Curie breast cancer database. This sample represented 0.8% of all breast carcinomas diagnosed. Pathological review could be performed on 122 cases when paraffin-embedded tissue was available. Each case was reviewed by a single pathologist on hematein-eosin-safran colored tissue sections. The criteria for diagnosis of medullary breast carcinoma were syncytial architecture in at least 75% of the tumor, welldefined margins, a moderate to pronounced lymphoplasmacytic infiltrate, nuclear polymorphism, and absence of glandular structure and in situ components (1) . When all these features were present, the tumors were classified as typical medullary carcinomas (TMC). When two or three of the above criteria were present along with a syncytial architecture, tumors were considered as atypical medullary carcinomas (AMC). Twenty-three cases in which diagnoses had been obtained from core biopsies (drill biopsies) were excluded from the study because they had been previously treated with chemotherapy or radiotherapy. Diagnoses were obtained from surgery in 71 cases; 95 of these were classified according to this classification, 52 as TMC and 19 as AMC. All other cases (27 pts) were not considered as medullary carcinomas and were excluded from the study.
The median age of the 71 patients was 51 years (range 27-82 years); 33 patients (46.5%) were postmenopausal. Median clinical tumor size was 25 mm (range 0-70 mm). Twenty-eight patients (39.4%) had T0T1 tumors and 43 (60.6%) had T2T3 tumors. Fifty-six patients (79%) had node status N0 and in 15 (21%) the node status was N1N2.
Treatment
Treatment was designed according to clinical tumor presentation. Fifty-five patients (77.5%) underwent a wide surgical excision followed by breast irradiation (Tab. I). Sixteen patients (22.5%) had a mastectomy. The median clinical tumor size was 25 mm (range 0-70 mm) in the 55 patients treated by wide excision and irradiation, and 30 mm (range 10-60 mm) in the 16 patients treated by mastectomy. Sixty (84.5%) patients underwent axillary node dissection during first local treatment. Eighteen of them (30%) had axillary node involvement (N+). Only one node was involved in 13 patients, two or three nodes were positive in two patients, and three patients had more than three nodes involved.
All 55 patients who had conservative treatment underwent breast irradiation but in only 24 patients was a boost delivered to the primary tumor site. The mean dose to the entire breast was 54 Gy (median 53 Gy; range 45-70 Gy). The median dose to the primary tumor site (including the boost) was 60 Gy (median 59 Gy; range 45-74 Gy). Only three patients underwent chest wall irradiation after mastectomy. The mean dose to the chest wall was 50 Gy. The regional lymph nodes were treated as follows: 40 patients underwent internal mammary node irradiation with a mean dose of 43 Gy; 18 patients underwent supraclavicular irradiation with a mean dose of 47 Gy, and 17 patients underwent axillary irradiation with a mean dose of 54 Gy.
Eleven patients (15.5%) received adjuvant chemotherapy. None received hormone treatment.
p53 immunohistochemistry
Immunostaining of p53 protein in tumor cells was determined as previously described (21) . Briefly, it was performed on 4 µm histological sections obtained from the surgical specimen or the biopsy sample, using D07 monoclonal antibody (1/400°dilution; Dako). Staining was visualized using streptavidin-biotin-peroxidase complexes (Vector, Vectastain). The rate of nuclear immunostaining of the p53 protein was scored as the percentage of positive cells. Positive tumors (p53+) had a score of ≥5%, whereas negative tumors (p53-) had a score of less than 5%. A positive control (a tumor known to carry p53 mutation) was included. 
Statistical methods
Comparisons between groups were made using the χ 2 test for categorical data, taking into account Yate's correction when necessary and Student's t test for the comparison of means. Distant metastasis-free survival rates and overall survival rates were calculated from the date of surgery to the date of the event of interest (distant metastasis, death) or to the date of last follow-up. Local recurrence was limited to breast or chest wall recurrence. Local recurrence rates, distant metastasis-free survival and overall survival rates were determined using Kaplan-Meier estimates (22) . Comparisons of survival distributions between putative prognostic factors were made by the log-rank test (23) . Ten-year rates were given with their 95% confidence intervals. P values <0.05 were considered significant.
RESULTS
The median follow-up for all 71 patients was 105 months (range 12-241 months). The median follow-up for the 56 survivors was 113 months (range 30-241). The crude rates of first events are shown in Table II . The 10-year overall survival rate was 81% (range 71.5-91.7). The 10-year metastasis-free survival rate was 81.4% (72.6-91.8). The 10-year breast or chest wall recurrence rate was 16.4% (5.8-25.8) . Univariate analysis of various prognostic factors (Tab. III) showed that axillary node involvement was a prognostic factor for overall survival (p<0.05) and for distant metastasis-free survival (p<0.02) in the 60/71 (84.5%) patients who underwent axillary node dissection. Adjuvant chemotherapy was another prognostic factor for overall survival (p<0.05) and distant metastasis-free survival (p<0.05). None of the other factors, including tumor size and histology (distinction between TMC and AMC), showed any significant impact on 
p53 protein accumulation and its prognostic value
Fifty-eight (82%) histological samples were available for p53 immunohistochemistry analysis. Among these, 33 (57%) were positive and 25 (43%) negative. Thirty p53-positive tumors (91%) had more than 60% labeled tumor cells, and the three others had about 20% labeled cells. We observed that the p53 distribution (percentage of labeled cells) was bimodal (0% or >60%). The median tumor size was 30 mm (15-70) and 20 mm (0-60) for p53+ and p53-tumors, respectively. The proportion of large tumors (more than 20 mm, T2T3T4) was significantly higher (p=0.01) in p53+ than p53-tumors (Tab. IV).
p53 positivity was not correlated with any of the other parameters tested. In particular, axillary node involvement in patients who had undergone axillary node dissection at initial surgery was not correlated with p53 staining. The p53 expression rate in the 58 patients was 59% for typical medullary carcinomas and 50% for atypical forms. The 10-year overall survival, metastasis-free survival and local relapse rates were not significantly different between patients with p53+ or p53-tumors (Tab. V).
DISCUSSION
This study of 71 patients with medullary breast carcinomas confirmed the results of several other studies (1) (2) (3) (4) (5) (6) as well as those of our previous study (7) , suggesting that MBC has a relatively good prognosis. The 10-year overall survival (OS), metastasis-free survival (MFS) and local recurrence (LR) rates were 81%, 81.4% and 16.4%, respectively, with a median follow-up of 113 months for survivors. Among the 60/71 (84.5%) patients who under- went primary axillary node dissection, 11/18 patients with axillary node involvement had only one involved node. As observed by others (2, 4, 5) , MBC seems to present a lower rate of axillary node involvement than ductal breast carcinomas. The prognostic factors found in our study were axillary node status and adjuvant chemotherapy; clinical tumor size did not influence prognosis, even though 59% and 29% of patients had tumors greater than 20 mm and 30 mm, respectively. Chemotherapy being a prognostic factor in univariate analysis was not a real surprise, because 73% of patients who received chemotherapy had axillary node involvement. However, we did not use multivariate analysis because our series did not have a sufficient number of patients.
Our MBC series has been the largest in which p53 IHC analysis was carried out. We showed that 57% of these tumors were p53+, which is in agreement with other studies on small series of patients (10, 14, (17) (18) (19) . Moreover, in the present study 91% of positive tumors were intensely stained (with more than 60% of labeled tumor cells), a finding which was also described elsewhere (14, 17) . We observed that IHC p53 distibution (percentage of labeled cells) was bimodal (0% or >60%). This could justify a new coding of p53 immunostaining as a logical variable (yes/no).
The choice of using a variable as dichotomous information for p53 IHC was probably not the best. We observed a bimodal distribution for p53 IHC results (percentage of labeled cells) and were unable to define a high risk prognostic group using a cutoff for this variable (contrary to Silvestrini et al; see ref. 24 ). It would be interesting to use more flexible regression models with a greater number of tumors analyzed (25) . These findings confirm the high rate of p53 protein accumulation in this particular pathological entity. In a previous study (20) we compared p53 immunostaining by IHC and TP53 mutations by DNA-S in 23 MBCs. The immunohistochemical p53+ rate was 61% and we found a strong correlation between the two techniques. In fact, of 17/23 tumors with TP53 gene mutations, 14 showed p53 overexpression by IHC. The remaining three tumors expressed short truncated p53 which was rather unstable and was not stained by IHC. These results support the assumption that positive p53 immunostaining is related to TP53 gene mutation. p53 overexpression was not correlated with poor outcome in the present study. The prognostic value of immunohistochemical expression of p53 in common breast carcinomas remains controversial. Some authors (26) (27) (28) reported a worse outcome for patients with p53 protein accumulation in breast tumors, while others did not find any significant prognostic value of IHC p53 expression (8, 18, 19, 21) . In a recent review Barbareschi et al (30) stated that these discrepancies were related to the different immunohistochemical techniques used to determine p53 status: tissue fixation, frozen conservation, antigen retrieval and antibodies. We used the monoclo-nal antibody DO7 because it had been proved to be one of the best antibodies for correlation analysis between p53 IHC and TP53 DNA-S (13) . Medullary breast carcinomas have been associated with mutations of other genes such as BRCA1 (31) and overexpression of proteins with a role in cell-cell adhesion (32) or mammary carcinoma progression (33) . These features may be related to a particular tumor behavior and more biological investigation will be needed to understand the mechanism of treatment sensitivity.
In conclusion, in this large series of 71 MBCs analyzed by p53 IHC we were able to confirm that this particular form of breast cancer has a favorable prognosis, despite its aggressive pathological features. Most medullary breast carcinomas had a high level of p53 protein accumulation as demonstrated by IHC. However, such accumulation had no prognostic value in this cohort of patients. Further studies are ongoing to determine the role of TP53 gene alterations in tumor genesis and treatment sensitivity of MBC. None of the differences was significant (p>0.05) OS, overall survival; MFS, metastasis-free survival; LR, local recurrence
